Nucleic acid amplification tests (NAATs) have frequently been the standard diagnostic approach when specific infectious agents are sought in a clinic specimen. They can be applied for specific agents such as S. pyogenes, or commercial multiplex NAATs for detection of a variety of pathogens in gastrointestinal, bloodstream, and respiratory infections may be used. NAATs are both rapid and sensitive. For many years, S. pyogenes testing algorithms used a rapid and specific group A streptococcal antigen test to screen throat specimens, followed, in some clinical settings, by a throat culture for S. pyogenes to increase the sensitivity of its detection. Now S. pyogenes NAATs are being used with increasing frequency. Given their accuracy, rapidity, and ease of use, should they replace antigen detection and culture for the detection of bacterial pharyngitis? Bobbi Pritt and Robin Patel of the Mayo Clinic, where S. pyogenes NAATs have been used for well over a decade with great success, will explain the advantages of this approach, while Richard (Tom) Thomson and Tom Kirn of the NorthShore University HealthSystem will discuss their concerns about this approach to diagnosing bacterial pharyngitis.
POINT
Acute pharyngitis is one of the most common diagnoses made in outpatient settings (1). Although viruses are responsible for the majority of cases, Streptococcus pyogenes (beta-hemolytic group A streptococci [GAS]) and, less commonly, other bacteria are estimated to cause 25% of the cases in adults and nearly 40% of the cases in children (2-4). Most cases of GAS pharyngitis are mild and self-limited, although potential complications include peritonsillar abscesses, otitis media, mastoiditis, cervical lymphadenitis, pneumonia, rheumatic fever, and poststreptococcal glomerulonephritis. Antimicrobial therapy may prevent these complications and may also shorten the duration of illness and potentially minimize the spread of infection to others; for these reasons, antibiotics are frequently administered, particularly to children and to adults with severe GAS pharyngitis (5, 6).We acknowledge that implicit in any diagnostic strategy is an assumption that results will be actionable, which, in the case of GAS pharyngitis, means that treatment would be administered. We realize that GAS pharyngitis, especially when it is nonsevere, is not universally treated and that there are geographic practice differences. There are a number of reasons for this, including that antibiotics have a relatively small effect in reducing symptoms and symptom duration, that rheumatic fever and poststreptococcal glomerulonephritis are rare in certain populations, that antibiotics risk disturbing the microbiome (and consequently increasing the risk of conditions such as thrush and Clostridium difficileassociated diarrhea), that antimicrobial use may result in allergies and other adverse drug effects, and also because of the associated cost and logistics of testing and treatment. Despite these controversies, which we will subsequently propose justify an outco...